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Abstract
Introduction: The prevalence of undiagnosed HIV is declining in Africa, and various HIV testing approaches are finding lower
positivity rates. In this context, the epidemiological impact and cost-effectiveness of community-based HIV self-testing (CB-
HIVST) is unclear. We aimed to assess this in different sub-populations and across scenarios characterized by different adult
HIV prevalence and antiretroviral treatment programmes in sub-Saharan Africa.
Methods: The synthesis model was used to address this aim. Three sub-populations were considered for CB-HIVST: (i)
women having transactional sex (WTS); (ii) young people (15 to 24 years); and (iii) adult men (25 to 49 years). We assumed
uptake of CB-HIVST similar to that reported in epidemiological studies (base case), or assumed people use CB-HIVST only if
exposed to risk (condomless sex) since last HIV test. We also considered a five-year time-limited CB-HIVST programme. Cost-
effectiveness was defined by an incremental cost-effectiveness ratio (ICER; cost-per-disability-adjusted life-year (DALY)
averted) below US$500 over a time horizon of 50 years. The efficiency of targeted CB-HIVST was evaluated using the number
of additional tests per infection or death averted.
Results: In the base case, targeting adult men with CB-HIVST offered the greatest impact, averting 1500 HIV infections and
520 deaths per year in the context of a simulated country with nine million adults, and impact could be enhanced by linkage
to voluntary medical male circumcision (VMMC). However, the approach was only cost-effective if the programme was limited
to five years or the undiagnosed prevalence was above 3%. CB-HIVST to WTS was the most cost-effective. The main drivers
of cost-effectiveness were the cost of CB-HIVST and the prevalence of undiagnosed HIV. All other CB-HIVST scenarios had
an ICER above US$500 per DALY averted.
Conclusions: CB-HIVST showed an important epidemiological impact. To maximize population health within a fixed budget,
CB-HIVST needs to be targeted on the basis of the prevalence of undiagnosed HIV, sub-population and the overall costs of
delivering this testing modality. Linkage to VMMC enhances its cost-effectiveness.
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1 | INTRODUCTION
The ambitious UNAIDS targets, set in 2014, of diagnosing
90% of people living with HIV, having 90% of those diagnosed
on antiretroviral treatment (ART) and having virological sup-
pression in 90% of those on treatment by 2020 has prompted
concerted programmatic efforts and review of progress
around these three indicators [1]. The annual volume of HIV
tests performed in sub-Saharan Africa (SSA) has more than
doubled over ten years.
Based on UNAIDS estimates, awareness of HIV status
among people living with HIV (PLHIV) continues to increase
rapidly, from 45% in 2014 [1] to 75% in 2017 [2]. Recent
population-based surveys (2015 to 2017) in Eastern and
Southern African countries found that between 52% and 85%
of PLHIV were aware of their status [3–7]. These may, indeed,
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be underestimates, as people tend to under-report HIV diag-
nosis [8]. Of concern though, despite increases in HIV testing,
challenges remain, as men, adolescents (10 to 19 years) and
key populations remain underserved by current testing strate-
gies [9,10] with lower proportions diagnosed than in the gen-
eral population [2]. To reach the first 90 target, and possibly
the even more ambitious future goals, it will be necessary to
implement approaches that reach those in need of HIV testing
and who are being missed.
Community-based HIV self-testing (CB-HIVST), defined as
the distribution of HIVST by approaches such as home distri-
bution, mobile outreach campaigns, distribution of HIVST at
workplaces, bars or educational establishments, is highly
acceptable, even to populations otherwise resistant to testing
[11]. It provides complementary coverage to other
approaches, including reaching people who have never tested
before, and is reasonably accurate [12]. CB-HIVST in urban
Malawi reached 68% of men aged ≥16 years and 89% of
young people (16 to 29 years) within the first year of imple-
mentation [13]. Similar levels of uptake were seen among men
and young people through CB-HIVST in rural Zimbabwe [14]
and slightly lower in a subsequent cluster randomized con-
trolled trial: 46.5% of men and 46.2% of people aged less than
25 [15]. In both Malawi and Zimbabwe, approximately a third
of those who accessed CB-HIVST reported never testing
before [13,15].
A measure of relevance for all HIV testing models is the
proportion of people tested in whom the test result is positive
(referred here as the test positivity rate). CB-HIVST models
report test positivity rates of approximately 8% [15] (excluding
retesting while taking ART and studies that used late-read,
given the issues with the stability of the test results when
reread after 72 hours), while facility-based HIVST distribution
(excluding studies that used late-read) have found test positiv-
ity rates as high as 11% [16] and even higher rates with dis-
tribution of HIVST among female sex workers (FSW): 27% in
Malawi [16] and 30% in Zimbabwe [17]. However, the positiv-
ity rate may not correspond to the proportion of tests that
actually result in a first diagnosis because retesting among
those previously diagnosed is common in all these studies,
albeit that this occurs also with standard HIV testing services
(HTS) [18]. The proportion of tests resulting in a first diagno-
sis has been shown to be an important driver of whether
HIVST distribution is cost-effective [19]. As countries get clo-
ser to reaching the first “90,” the prevalence of undiagnosed
HIV will decline further and test positivity rates of HIV testing
models will fall, potentially impacting on whether different
HIV testing approaches remain cost-effective.
The HIV Self-Test AfRica (STAR) project recently estimated
the unit cost per individual tested across health facilities test-
ing services [20] and CB-HIVST sites in Zimbabwe, Malawi
and Zambia [21]. Using a mathematical model previously used
to evaluate the potential cost-effectiveness of HIVST [19], we
aimed to identify which HIV epidemic and programmatic attri-
butes and in which populations in SSA CB-HIVST would have
the greatest epidemiological impact, and whether CB-HIVST
could be cost-effective, using the costs per individual tested
estimated in STAR. This builds on another piece of work using
the same mathematical model aimed at estimating the cost of
HIV testing per diagnosis at which HIV testing programmes
are cost-effective [22].
2 | METHODS
2.1 | Synthesis model
We used an individual-based stochastic model of HIV transmis-
sion, progression and the effect of ART in adult populations in
SSA. More detailed description of the model can be found in
previous papers [19,22,23] and in the S1. Each time the model
program is run, it samples values of variables including the num-
ber of short-term condomless sex partners, whether they have
a long-term condomless sex partner, HIV testing, HIV acquisi-
tion, and additionally, for people with HIV, viral load, CD4 count,
use of specific ART drugs, adherence to ART, resistance to
specific drugs and risk of HIV-related death, each updated in
three-month time steps from 1989.
The model provides means by which we can quantify the
health effects of testing which occur via increases in the pro-
portion of PLHIV on ART, with the consequent beneficial
effects on both individual health and onward transmission.
This allows estimation of the overall number of disability-
adjusted life years (DALYs) averted in the whole adult popula-
tion as a result of these effects. Possible linkage to pre-expo-
sure prophylaxis for people tested negative is not included.
Parameters intrinsic to biological properties of HIV trans-
mission and progression and effects of ART have been
informed by data from European cohorts and confirmed by
data from Africa, where available, and are kept fixed. We sam-
pled parameter (see distributions in the Table S1) values relat-
ing to sexual behaviour, HIV transmission, HIV testing
(including proportion of the population who is willing to test
only if symptomatic or if HIVST is available), linkage to care
and retention in care and on ART in order to generate a range
of scenarios applicable to different settings in SSA (hereafter
referred to as setting-scenarios) in terms of HIV epidemic,
HIV testing and ART programme characteristics.
We track a population of approximately 20,000 living adults
(15 to 64 years old; increasing over time) which is then scaled
up to obtain estimates relevant for a population of around nine
million (in 2018, Zimbabwe 7.8 million [24], Malawi 9.8 million
[25], Zambia 8.2 million [26]). We excluded simulations where
in 2004 there was an HIV prevalence among women below 5%
or above 30% and in 2016 a number of women having condom-
less transactional sex (defined as having had more than three
condomless sex partners in a three-month period in the last
year) below 1460 or above 146,000. These were deemed
implausible given the estimates from sentinel antenatal clinics
[27] and on the percentage of women who are women having
transactional sex (WTS) in SSA [28]. In total, 150 setting-scenar-
ios were obtained. Table 1 shows the characteristics of the 150
setting-scenarios in 2017, along with examples of observed data
(see S1 for more information).
2.2 | Implementation options under consideration
For each setting-scenario, we projected forward for 50 years
from 2018 to 2068 under seven possible CB-HIVST imple-
mentation options (see Table 2). The reference option
assumed that the current pattern and level of testing contin-
ues, including in WTS, in pregnant women (twice per preg-
nancy), in people presenting with potential HIV symptoms and
in men presenting for voluntary medical male circumcision
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(VMMC), but that no CB-HIVST is available. In the other six
implementation options, HIVST is introduced through commu-
nity-based distributors in addition to the current testing in one
of the following sub-populations: young people (15 to 24 years),
WTS and adult men (25 to 49 years). In these implementation
options, HIVST is assumed to partially replace standard HTS
Table 1. Characteristics of the HIV epidemic/ART programme setting-scenarios in 2017 in SSA countries with an adult population
age 15 to 64 years approximately nine million
Indicator
Median (90% range) across
Setting-scenarios (n = 150) Examples of observed data
Population size (in million)
Overall (15 to 64 years) 9.1 (8.2 to 9.9) Zimbabwe 15 to 64 (2018): 7.8 million [24]
Malawi 15 to 64 (2018): 9.8 million [25]
Zambia 15 to 64 (2018): 8.2 million [26]
Lesotho 15 to 64 (2018): 1.2 million [45]
Women (15 to 49 years) 4.1 (3.8 to 4.3)
Men (15 to 49 years) 3.9 (3.6 to 4.1)
Young (15 to 24 years) 3.2 (3.1 to 3.2)
Adult men (25 to 49 years) 2.3 (2.0 to 2.6)
WTS (15 to 64 years) 0.16 (0.07 to 0.25)
HIV prevalence
Overall (15 to 49 years) 12.8% (4.7% to 27.5%) Zimbabwe DHS 2015 [10]:14%
Tanzania DHS 2011 [46]: 5%
Uganda DHS 2011 [47]: 9%
Lesotho DHS 2014 [48]: 25%
Women (15 to 49 years) 13.0% (4.5% to 29.4%)
Men (15 to 49 years) 12.6% (5.0% to 23.3%)
Prevalence of undiagnosed HIV
Overall (15 to 64 years) 2.1% (0.7% to 4.8%) Malawi PHIA 2016 [4]: 2.9%
Zimbabwe PHIA 2016 [6]: 3.8%
Zambia PHIA 2016 [5]: 4.0%
Rwanda [38]: approximately 0.3%
(Survey estimates could be overestimates due to
undisclosed diagnosed HIV [8])
Women (15 to 49 years) 1.2% (0.4% to 3.5%)
Men (15 to 49 years) 3.3% (1.0% to 7.0%)
HIV incidence (age 15 to 49 years)
per 100 person years
0.91 (0.23 to 2.19) Malawi PHIA 2016 [4]: 0.37%
Zimbabwe PHIA 2016 [6]: 0.45%
Zambia PHIA 2016 [5]: 0.66%
Swaziland [7]: 2.4%
Lesotho [3]: 1.5%
Mbongolwane and Eshowe published
in 2014 (KZN) [49]: 1.2%
Number of HIV tests in year
Overall (15 to 64 years) 2,300,000 (1,293,000 to 3,327,000) Zimbabwe 2.2 million (2015) [50],
Malawi 1.9 million (2014) [51]Women (15 to 49 years) 1,485,000 (708,000 to 2,271,000)
Men (15 to 49 years) 796,000 (461,000 to 1,072,000)
ANC services 721,000 (96,000 to 1,595,000)
WTS (15 to 64 years) 78,000 (30,000 to 142,000)
Symptomatic (PLHIV)a 22,000 (8,000 to 47,000)
Symptomatic (HIV–) 181,000 (160,000 to 200,000)
VMMC services 150,000 (114,000 to 189,000)
Percentage of tests resulting in
new HIV diagnosisb
Overall (15 to 64 years) 3.2% (1.1% to 8.3%) Observed data estimates are susceptible to bias
due to rediagnosis of people who do not report
previous diagnosis. 6% to 55% depending
on group [52]
Malawi first quarter 2016 [53]: 5%
Women (15 to 49 years) 2.4% (0.7% to 6.3%)
Men (15 to 49 years) 5.1% (1.6% to 11.3%)
Young (15 to 24 years) 2.2% (0.4% to 5.7%)
ANC services 2.9% (0.6% to 17.5%)
WTS (15 to 64 years) 18.0% (3.3% to 35.1%)
Symptomatic 9.4% (3.5% to 18.2%)
VMMC services 3.2% (0.6% to 6.9%)
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(see Table 2). In our base case, CB-HIVST implementation
options involved continuous CB-HIVST availability for the entire
timeframe (50 years). We based assumptions on accuracy of
CB-HIVST on the overall results for oral fluid HIVST in a sys-
tematic review and meta-analysis of HIV self-test performance
in field settings, including low- and middle-income countries
(sensitivity of 93.9% and specificity of 99.2%) [12]. However, we
made the conservative assumption that neither the standard
HTS nor the CB-HIVST in SSA can detect HIV within three
months of infection (the time step in the model). In addition, we
assumed that a positive result using a CB-HIVST is not suffi-
cient to make an HIV diagnosis but that a confirmatory test per-
formed by a trained healthcare worker is required for the
person to be diagnosed with HIV and be able to be linked to
care and treatment. The main assumptions related to HIVST are
summarized in Table 3 (and Table S2).
Table 1. (Continued)
Indicator
Median (90% range) across
Setting-scenarios (n = 150) Examples of observed data
Proportion tested in past year
Women (15 to 49 years) 29% (15% to 41%) Zimbabwe DHS 2015 [10]: 49% women, 36% men
(age 15 to 49 years)
Namibia DHS 2013 [54]: 49% women, 38% men
(age 15 to 49 years)
Nigeria DHS 2013 [55]: 10% women, 10% men
Men (15 to 49 years) 19% (12% to 27%)
Women (15 to 24 years) 25% (11% to 38%)
Men (15 to 24 years) 17% (11% to 23%)
When symptomatic (PLHIV)a,c 16% (9% to 24%)
In pregnancy (15 to 49 years) 93% (30% to 98%)
WTS (15 to 64 years) 39% (22% to 52%)
Proportion of HIV-positive people diagnosed
Overall (15 to 64 years) 83% (73% to 90%) Malawi PHIA 2016 [4]: 73%; 76% in women, 67% in men
Zimbabwe PHIA 2016 [6]: 74%
Zambia PHIA 2016 [5]: 67%
Mbongolwane and Eshowe (KZN) published in 2014 [49]:
75%
District of Chiradzulu (rural Malawi) 2013 [56]: 77%
Botswana 2013 to 2015 [57]: 78%, higher in women
than men
Survey estimates likely to be over-estimates due to
undisclosed diagnosed HIV [8]
Women (15 to 49 years) 90% (79% to 95%)
Men (15 to 49 years) 74% (61% to 85%)
Women (15 to 24 years) 79% (56% to 88%)
Men (15 to 24 years) 43% (26% to 57%)
WTS (15 to 64 years) 75% (58% to 87%)
Proportion of diagnosed people on ART
Overall (15 to 64 years) 88% (59% to 92%) Malawi PHIA 2016 [4]: 89%
Zimbabwe PHIA 2016 [6]: 87%
Zambia PHIA 2016 [5]: 85%
Botswana 2013 to 15 [57]: 85%
Women (15 to 49 years) 89% (59% to 92%)
Men (15 to 49 years) 87% (56% to 91%)
Women (15 to 24 years) 89% (42% to 93%)
Men (15 to 24 years) 79% (33% to 91%)
WTS (15 to 64 years) 90% (50% to 94%)
Proportion of people on ART
with VL < 1000 copies/mL
Overall (15 to 64 years) 85% (81% to 89%) World Bank South Africa [58]: 60% to 88% over districts
Malawi PHIA 2016 [4]: 91%
Zimbabwe PHIA 2016 [6]: 87%
Zambia PHIA 2016 [5]: 89%
District of Chiradzulu (rural Malawi) 2013 [56]: 91%
Mbongolwane and Eshowe (KZN) published in
2014 [49]: 90%
Rural Uganda and Kenya [59]: 90%
Botswana 2013 to 2015 [57]: 94%
(among citizens of Botswana)
ANC, antenatal care; ART, antiretroviral therapy; DHS, Demographic and Health Surveys; KZN, KwaZulu-Natal; PHIA, Population-based HIV
Impact Assessment; PLHIV, people living with HIV; VMMC, voluntary male medical circumcision; WTS, women having transactional sex.
aSymptoms of a WHO Stage 3 or 4 condition; bThis is also referred to as yield. In our model, this is the same as test positivity rate as within the
Synthesis model people who received a diagnosis of HIV cannot test again, so this is the ratio between the number of new diagnoses and the
number of tests performed; cin this case is not in the past year but of those symptomatic/pregnant in a specific time period.
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In addition, we considered several sensitivity analyses around
the implementation option of CB-HIVST being available for
adult men aged 25 to 49 years: (1) five-year time-limited CB-
HIVST programme; (2) assuming that the increase in the
number of tests obtained by introducing CB-HIVST is
instead introduced with standard HTS (to understand, in
case CB-HIVST was not cost-effective, whether this was due
to characteristics intrinsic to CB-HIVST or whether any
increase in testing is not cost-effective regardless of mode
of testing); (3) assuming that 10% of men with negative CB-
Table 2. Description of implementation options
Core testing
Population in which
CB-HIVST is available
Possibility of using
CB-HIVST if no CLS
since last test
Replacement of
HTS with CB-HIVST
Ref Current level of testing continues,
in particular testing in:
• General population (including WTS)
• In pregnant women (twice per pregnancy)
• In people presenting with potential
HIV symptoms
• In men presenting for VMMC
None Not applicable Not applicable
1 Young people (15 to 24 years) Yesa 30%b
2 Adult men (25 to 49 years) 30%b
3 WTS (15 to 64 years) 50%d
4 Young people (15 to 24 years) Noc 30%b
5 Adult men (25 to 49 years) 30%b
6 WTS (15 to 64 years) 50%d
CB-HIVST, community-based HIV self-testing; CLS, condomless sex; HTS, HIV testing services; PLHIV, people living with HIV; VMMC, voluntary
medical male circumcision; WTS, women reporting transactional sex.
aThey can HIVST only once per year, but they can HIVST even if they had HTS in the last year (% self-tested per year indicated in Table 4). bStudy
offered standard HTS or HIVST and 30.9% men opted for HIVST [60]. cThey can use HIVST only if they had condomless sex since last test (HTS
or CB-HIVST) but they can test more than once per year if having CLS. d54% of women who attended a FSW clinic where provider initiated testing
and counselling was available (n = 604) and were offered HIVST opted for it [17]. Higher rate of substitution has been reported as well [61,62].
Table 3. Assumptions on CB-HIVST
Parameter Value assumed for base case Source
Sensitivity of CB-HIVST 93.9% [12]
Specificity of CB-HIVST 99.2% [12]
Sensitivity of HTSa 98% [63]
Specificity of HTSa 99.2% [64]
Confirmatory HTS following
positive CB-HIVST
50% by three months, 78% by
one year from positive CB-HIVSTb
At six weeks: 50% in the arm without incentive
after excluding those retesting on ART [15]
Evidence on disclosure from [13] and %
self-reported linking to care in STAR
Proportion initiated on ART of those
who had a positive
(not previously diagnosed) CB-HIVST
36% by three monthsc At six weeks: 30% in the arm without incentive
after excluding those retesting on ART [15]
Change in condomless sex
in those who are tested HIV
positive by HTS
With long-term partner: none,
with short-term partner: 17%
in the first six months, 9% after
[65,66]
Change in condomless sex
in those tested HIV negative by HTS
No change [67]
Among FSW no difference in condom use, but
reduction in number of partners following HIVST
at four months
[68]
Change in condomless sex
after CB-HIVST (and before
any confirmation with HTS)
No change Among FSW no difference in condom use, but
reduction in number of partners following HIVST
at four months [68]
ART, antiretroviral therapy; CB-HIVST, community-based HIV self-testing; HTS, HIV testing services.
aAssumed as facility-based rapid diagnostic test. bIt is assumed that people can have a confirmatory test as a consequence of a positive CB-HIVST only
within one year of the positive CB-HIVST. cThis is the median proportion initiated on ART at three months; the probability of initiating ART in people
engaged to care is 0.8 per three months; for people diagnosed with HIV not linked to care by three months since diagnosis, there is a probability of
linkage to care (or re-engaging into care if lost) per three months which is sampled from a distribution 0.1 (90% range: 0.03 to 0.32).
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HIVST and aged 25 to 50 link to VMMC; and (4) assuming a
discount rate of 10% for both costs and health benefits. In
the base case, we considered the conventional discounting rate
of 3.0% per annum [29].
To reduce stochastic variability, we performed two repeti-
tions of the projections of the population from 2018 for each
implementation option in each simulation, except for the
options involving WTS, where four repetitions were per-
formed due to the small sample size of this subgroup, or in
the 5-year CB-HIVST distribution implementation option, and
we calculated the mean across these repetitions.
We assumed that all people are eligible for ART at diagno-
sis from 2017 and that viral load monitoring was used from
mid-2016 (at six and twelve months, and then annually).
Disability weights to calculate DALYs were derived from a
comprehensive study (conditions included are: TB, WHO
Stages 4 and 3) [30].
2.3 | Costs and cost-effectiveness approach
We used the fully loaded average recurrent cost per CB-HIVST
estimated in STAR in Zimbabwe and Malawi, respectively, US
$10.18 and US$5.61 [21] (see further details in the S2), and a
cost per person tested for HIV testing performed by a health-
care worker (except for community-based), derived from [31],
of, respectively, US$8.66 for Zimbabwe (US$9.37 if positive)
and US$4.82 for Malawi (US$5.82 if positive). Other unit costs
are provided in the Table S3 but, in brief, the annual cost (in-
cluding 20% of supply chain costs) of the first-line regimen of
efavirenz, lamivudine, tenofovir is US$98 per person [32], pro-
gramme costs for clinic visits (not including drug or viral load
or CD4 count tests) are US$20 per three months [33,34] with
an assumed reduction to US$10 per three months when viral
load is measured to be <1000 copies/mL [20].
The cost-effectiveness analysis was undertaken from the
health provider perspective. Costs were estimated in 2016 US
dollars. Health outcomes were quantified in DALYs averted and,
as mentioned above, a discount rate of 3% was applied to both
costs and health outcomes [29]. We calculated incremental costs
and DALYs averted for the CB-HIVST implementation options
compared with the reference over a 50-year time horizon, in
order to capture all costs and effects relevant to this decision
problem. The CB-HIVST implementation option was deemed
cost-effective if the incremental cost-effectiveness ratio (ICER)
was below US$500 per DALY averted, or if it resulted in both
cost savings and DALYs averted. This use of the cost-effective-
ness threshold reflects the health foregone (opportunity costs)
due to resources committed to HIV testing consequentially being
unavailable to provide other interventions (i.e. so that US$500
reflects the cost-per-DALY-averted of these foregone activities
[35,36]). Severe constraints on overall healthcare spending in
low-income countries in the region, notably for Malawi [37] mean
that this cost-effectiveness threshold is only likely to be relevant
for resource allocation within the HIV programme, which is over-
whelmingly reliant on donor funds.
3 | RESULTS
Overall, the median (90% range) HIV prevalence across set-
ting-scenarios in 2017 was estimated to be 12.8% (4.7% to
27.5%), the prevalence of undiagnosed HIV (ratio between the
number of PLHIV who are undiagnosed and the entire popula-
tion) was 2.1% (0.7% to 4.8%) and the test positivity rate
(which in our model corresponds to the proportion of tests
resulting in a first diagnosis) was 3.2% (1.1% to 8.3%) (see
Table 1). As expected, the test positivity was higher for
women having condomless transactional sex (18.0%), adult
men 15 to 49 (5.1%) and symptomatic individuals (9.4%). We
modelled CB-HIVST introduction in three independent sub-
populations: young people (aged 15 to 24 years) amounting to
3.2 million people in 2017 (35% of people aged 15 to
64 years), adult men (aged 25 to 49 years) amounting to
2.3 million men (2.0 to 2.6; 25% of people aged 15 to
64 years) and WTS (160,000 women; 70,000 to 250,000;
1.8% of people aged 15 to 64 years).
Table 4 illustrates the scope of implementation and the epi-
demiological impact of the considered implementation options;
the highest average number of tests was required when CB-
HIVST was available continuously in the future; people self-
tested even if not exposed to risk of HIV acquisition (no sex
without condom) since last test; and CB-HIVST was available
for young people (3,744,000 additional test/year compared to
the reference option, +97%). Targeting adult men entailed
2,631,300 additional tests/year (+68%) and targeting WTS
resulted in 222,400 additional test/year (+6%). Of note, we
assumed that similar uptake of CB-HIVST could be achieved
nationally as reported for the STAR subnational demonstration
projects and cluster randomized trials: respectively, 87% in
young people, 73% in WTS and 71% in adult men.
In terms of epidemiological impact, in the base case for the
implementation options offering CB-HIVST to adult men had
the highest impact, with an average (across setting-scenarios)
of 1500 HIV infections averted per year, followed by targeting
of young people (1490 HIV infections averted per year) and
WTS (1430 HIV infections averted per year). Similarly, deaths
averted (in PLHIV and without HIV) were highest when CB-
HIVST was targeted at adult men (520 death averted/year),
followed by young people (360 death averted/year) and WTS
(330 death averted/year). Health benefits from CB-HIVST for
adult men were enhanced if 10% of men with negative HIVST
in the 25- to 50-year age group link to VMMC (1720 HIV
infections averted per year vs. 1500; 580 deaths averted/year
vs. 520). However, in terms of numbers-needed-to-test to
avert one new HIV infection, targeting WTS was by far the
most efficient strategy requiring 160 additional tests per HIV
infection averted, compared to 2500 for young people and
1750 for adult men. For deaths, the equivalent numbers of
additional tests was 670 per death averted for strategies tar-
geting WTS, compared to 10,460 for young people and 5060
for adult men. Numbers of additional tests needed were
almost halved for young people if CB-HIVST was taken up
only if they had condomless sex since their last test. Similarly,
the five-year time-limited CB-HIVST programme reduced the
number of additional tests per HIV infection averted and per
death averted to 180 and 710 respectively.
Figure 1 shows the cost per DALY averted (compared to
the reference option) using a 50-year timeframe and two sets
of costs for CB-HIVST and HTS for the base case scenarios
(assuming a maximum of one standards HTS annually, but
regardless of sexual risk-taking) and for several sensitivity anal-
yses. The cost per DALY averted using a 20-year timeframe is
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illustrated in Figure S1. In addition, variation in CB-HIVST
cost-effectiveness in different settings was considered by strati-
fying simulations by prevalence of undiagnosed HIV (quartiles).
The timeframe considered has a crucial impact on cost-
effectiveness: under the 50-year timeframe, introduction of
CB-HIVST is cost-effective if introduced among WTS (whether
the use is limited to when having condomless sex or not), for
a five-year programme among adult men (unless the preva-
lence of undiagnosed HIV is below approximately 1% and cost
per CB-HIVST is US$10.18) and among adult men provided
that the prevalence of undiagnosed HIV is relatively high
(>3% if cost per CB-HIVST is US$5.61, >5.5% if US$10.18).
However, when considering a 20-year time horizon, it was
cost-effective only when offered to WTS in setting with a
Table 4. Mean over 50 years (2018 to 2068) of intermediate measures describing the implementation and the epidemiological
impact of the options considered (across 150 setting-scenarios)
Implementation
option
Sub-
population
receiving
HIVST
Number of
HIV tests
(HTS or
HIVST)/year
– age 15 to
64 years
(additional test
compared to no
intervention,
relative
increase)
Number
of new
diagnoses
per year
(age 15 to
49 years)
Number
of new
diagnoses
per year in
the sub-
population
of interest
% tested in
the past
year (HTS or
HIVST; age
15 to 49
years)
% tested in
the past
year in the
sub-population
of interest
% self-
tested
in the
past year
(age 15 to
49 years)
% self-tested
in the past
year in the
sub-population
of interest
% ever
tested
(HTS or
HIVST; age
15 to 49
years)
% ever
tested
(HTS or
HIVST) in
the sub-
population
of interest
No Intervention NA 3,860,300 (-) 58,500 Young:
16,500
25% Young: 21% 0% Young: 0% 74% Young: 50%
WTS: 15,400 WTS: 39% WTS: 0% WTS: 85%
Adult men:
22,900
Adult men:
21%
Adult men:
0%
Adult men:
82%
HIVST is
available
– no
requirement
for CLS –
base
case
Young
people
7,604,300
(3,744,000,
+97%)
55,500 18,900 51% 91% 35% 87% 98% 99%
WTS 4,082,800
(222,400,
+6%)
55,000 16,300 26% 86% 2% 73% 79% 99%
Adult men 6,481,600
(2,621,300,
+68%)
57,800 24,700 42% 76% 24% 71% 81% 99.6%
HIVST is
available
– requirement
for CLS
Young
people
5,947,900
(2,087,600,
+54%)
55,300 17,900 30% 35% 10% 24% 78% 54%
WTS 4,088,400
(228,100,
+6%)
54,700 15,900 26% 58% 1% 39% 78% 86%
Adult men 6,150,400
(2,290,000,
+59%)
57,100 23,800 33% 47% 12% 35% 78% 90%
HIVST is
available,
next five
years
Adult men 4,082,800
(222,400,
+6%)
55,700 21,800 27% 27% 3% 7% 79% 93%
HIVST is
available
– as good
as HTS
Adult men 6,457,200
(2,596,900,
+67%)
58,200 25,200 42% 75% 24% 70% 81% 99.6%
HIVST is
available
– linkage to
VMMC
Adult men 6,485,800
(2,625,500,
+68%)
57,100 24,200 42% 76% 24% 71% 81% 99.6%
CB-HIVST, community-based HIV self-test; CLS, condomless sex; HTS, HIV testing services; NA, not applicable; VL, viral load; VMMC, voluntary
medical male circumcision; WTS, women having transactional sex.
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prevalence of undiagnosed HIV above 5.5% and if the cost of
CB-HIVST was relatively low ($5.61). The cost of delivering
CB-HIVST, not surprisingly, plays a crucial role in determining
the ICER. Applying higher discounting rates of 10% to addi-
tional costs and health benefits renders CB-HIVST among
adult men not cost-effective regardless of the prevalence of
undiagnosed HIV.
4 | DISCUSSION
CB-HIVST offers the opportunity to reduce the “testing gap”
in men, young people and WTS: subgroups that are hard to
reach with standard HIV testing services. Here, we show that,
when health benefits and costs are considered over a rela-
tively long time horizon, targeted CB-HIVST can be cost-
% who never
tested
before, out
of those
who use
HIVST
for the
first time
% of HIVST
resulting in a
diagnosis
(referred
to as positivity
rate; age
15 to
49 years)
% of HIV-
positive
people
diagnosed
(age 15
to 49 years)
% of
HIV-positive
people
diagnosed in
the sub-
population
of interest
% of people
with HIV
and VL > 1000
(out of the
entire
population;
age 15 to
64 years)
Number of
condomless
(short term and
long term)
infectious
partnership
Number of
people living
with HIV with
VL > 1000
copies/mL
Number of
deaths
per year
(averted
compared
to the no
intervention)
Number of
HIV infections
per year
(averted
compared to
the no
intervention)
Number of
additional
tests per
HIV infection
averted
(per death
averted)
NA NA 86% Young: 67% 3.2% 944,500 416,900 43,300 (-) 17,560 (-) - (-)
WTS: 74%
Adult men:
80%
97% 0.28% 89% 84% 2.8% 871,800 367,900 43,000 (360) 16,060 (1490) 2500 (10,460)
34% 2.92% 88% 81% 2.9% 875,900 380,700 43,000 (330) 16,130 (1430) 160 (670)
21% 0.80% 91% 94% 2.7% 876,800 351,700 42,800 (520) 16,060 (1500) 1750 (5060)
20% 0.61% 88% 77% 2.9% 882,700 376,800 43,000 (340) 16,160 (1400) 1490 (6070)
6% 3.42% 88% 81% 2.9% 866,700 380,500 43,000 (340) 16,040 (1520) 150 (660)
3% 1.03% 90% 91% 2.8% 884,200 361,000 42,900 (460) 16,100 (1460) 1570 (4960)
25% 1.31% 88% 84% 2.9% 907,700 384,000 43,000 (310) 16,340 (1220) 180 (710)
21% 0.92% 93% 96% 2.7% 874,400 346,900 42,800 (550) 15,970 (1590) 1640 (4760)
21% 0.78% 92% 94% 2.7% 879,300 348,700 42,800 (580) 15,830 (1720) 1520 (4530)
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effective using strategies that vary by the prevalence of undi-
agnosed HIV. The most efficient approaches are targeted to
WTS, which remain cost-effective at all levels of prevalence of
undiagnosed HIV in our setting-scenarios (approximately 1%
to 5.6%). A five-year time-limited CB-HIVST programme can
also be cost-effective for adult men, at all levels when using
cost for the CB-HIVST of US$5.61 and at levels of prevalence
of undiagnosed HIV above 1% when using CB-HIVST cost of
US$10.18. This is due to the fact that by considering an inter-
vention that lasts for only five years, the cost is reduced sub-
stantially and the HIV testing earlier in time is more beneficial
as the undiagnosed prevalence is declining over time. Indefi-
nite introduction of CB-HIVST for adult men is cost-effective
only at relatively high initial prevalence of undiagnosed HIV,
depending on the cost of CB-HIVST. When considering CB-
HIVST in WTS, it is important to note that we have assumed
the same cost per person tested as in the other populations.
Data on these costs have been collected as part of the STAR
project but final estimates are not available yet.
Current estimates of the prevalence of undiagnosed HIV
from national surveys range from 0.3% in Rwanda [38] to 4%
in Zimbabwe [6] and Zambia [5] with considerable variation
also within countries. For example, in Zimbabwe estimates
range from 2.9% in Manicaland to 5.8% in Matabeleland South
[6] and in Zambia from 1.9% in Muchinga to 5.3% in Lusaka
[5]. Thus, health benefits from investments at the national
level can be maximized through implementation of different
HIVST strategies in different geographical regions [39,40]. The
corollary of this argument is that implementers may need to
limit CB-HIVST efforts, potentially through periodic campaign
style implementation, in settings with very low HIV awareness,
as the benefits of testing people with very low probability of
being infected will be limited. Community-based distribution
of HIVST kits can take place in different ways and this partly
drives the differences in costs seen in Zimbabwe compared to
Malawi. The costs of government implementation CB-HIVST
may be lower than estimated in the STAR project [21] and we
anticipate that delivery costs will continue to fall due to econo-
mies of scale and efficiencies from increasing familiarity with
this concept. This would increase the likelihood of HIVST pro-
grammes being cost-effective. However, the issue of “diminish-
ing returns” will reduce the cost-effectiveness of all HIV testing
strategies as the prevalence of undiagnosed HIV falls. In the
context of declining undiagnosed prevalence, programme met-
rics such as the cost of testing per new HIV diagnosis have
potential use for monitoring programme cost-effectiveness and
in other work we have described approaches to link this metric
to programme cost-effectiveness [22].
Secondary distribution models, where HIVST kits are dis-
tributed to sexual partners of WTS or pregnant women,
which have high positivity rates and similar delivery costs
[41,42], are likely to offer cost-effective approaches to dis-
tributing HIVST [43]. Additionally, improving linkage of those
who test HIV negative to HIV prevention services may
improve cost-effectiveness. In our sensitivity analysis, we
explored the possibility that 10% of men with a negative
CB-HIVST result are linked into VMMC and show that this
would improve the benefits and cost-effectiveness of CB-
HIVST targeted to men (considering the additional cost of
VMMC). While not included in the scenarios modelled, the
 ICER, Mean Cost per DALY averted (Addional cost in US$ million /DALYs averted in 1,000s) 
 High cost of CB-HIVST (US$10.18) and HTS  
(US$8.66 if negave; US$9.37 if posive) 
Low Cost of CB-HIVST (US$5.61) and HTS†  
(US$4.82 if negave; US$5.82 if posive) 
Overall Prevalence of undiagnosed HIV Overall Prevalence of undiagnosed HIV 
0.3 - 1.6% 1.6 – 2.4% 2.4 – 3.7% 3.7 – 7.4% 0.3 - 1.6% 1.6 – 2.4% 2.4 – 3.7% 3.7 – 7.4% 
HIVST is available – no 
requirement for CLS 
(base case) 
Young 2,000 
(943/483) 
5,400 
(965/177) 
2,800 
(947/339) 
1,700 
(950/574) 
1,100 
(913/837) 
1,100 
(528) 
3,100 
(545) 
1,600 
(529) 
930 
(535) 
600 
(504) 
WTS 120  
(51/412) 
380 
(75/201) 
220 
(64/290) 
100 
(53/517) 
20 
(12/638) 
60 
(27) 
260  
(53) 
140 
(40) 
50 
(28) 
-20 
(-13) 
Adult men 880  
(693/786) 
2,700 
(732/267) 
1,200 
(700/605) 
770 
(700/908) 
470 
(642/1,352) 
520 
(410) 
1,600 
(421) 
670 
(405) 
470 
(426) 
290 
(388) 
Sensivity analyses 
HIVST is available – 
requirement for CLS 
Young 1,200 
(515/419) 
3,000 
(488/161) 
1,700 
(492/282) 
980 
(487/498) 
810 
(590/730) 
680 
(286) 
1,700 
(282) 
970 
(274) 
560 
(277) 
430 
(311) 
WTS 110  
(45/410) 
370 
(72/196) 
210 
(62/293) 
70 
(36/525) 
20 
(10/622) 
50  
(20) 
260 
(51) 
130 
(38) 
20 
(13) 
-30 
(-20) 
Adult men 930 
(591/636) 
2,500 
(568/226) 
1,100 
(580/540) 
750 
(549/729) 
640 
(665/1,039) 
550 
(347) 
1,500 
(330) 
620 
(336) 
450 
(331) 
370 
(389) 
HIVST is available for the 
next 5 years  
Adult men 
 
230 
(115/502) 
690 
(142/205) 
310 
(121/388) 
220 
(122/559) 
90 
(77/851) 
150 
(74) 
470  
(95) 
200 
(78) 
150 
(83) 
50 
(40) 
HIVST is available - as 
good as HTS 
680  
(594/869) 
 1,800 
(612/335) 
970 
(602/621) 
560 
(605/1,091) 
390 
(560/1,420) 
410 
(359) 
1,100 
(354) 
580 
(358) 
350 
(379) 
240 
(346) 
HIVST is available – 
linkage to VMMC‡ 
780 
(693/887) 
2,000 
(739/367) 
1,100 
(705/665) 
660 
(693/1,052) 
440 
(634/1,455) 
460 
(410) 
1,200 
(427) 
620 
(411) 
400 
(419) 
260  
(379) 
Base case – 10% 
discounng rate 
1,600 
(250/154) 
4,400 
(257/59) 
2,200 
(250/116) 
1,400 
(251/181) 
940 
(243/259) 
1,000 
(159) 
2,600 
(155) 
1,300 
(154) 
900 
(163) 
630 
(162) 
Figure 1. Cost per DALY averted of community-based HIVST by implementation option, prevalence of undiagnosed HIV (quartile) and cost
of testing in the sub-population indicated – 2018 to 2068.
Cost-saving; ICER $0-$249 per DALY; ICER $250-$499 per DALY; ICER $500-$999 per DALY; ICER $1,000-$2,499 per DALY; ICER
≥$2,500 per DALY; †DALYs averted not reported when showing the ICERs using the cost of CB-HIVST of $5.61 and HTS of $4.82, as the same
regardless of the costs assumed; ‡10% of men with negative HIVST and aged 25-50 link to circumcision; CB-HIVST: community-based HIVST;
DALY: disability-adjusted life years; HIVST: HIV self-test; HTS: HIV testing services; ICER: incremental cost-effectiveness ratio; VMMC: voluntary
medical male circumcision; WTS: women having transactional sex;
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addition of linkage to pre-exposure prophylaxis could also
enhance impact of HIVST.
Previous cost-effectiveness analysis of adding CB-HIVST to
existing testing services are available from urban Blantyre,
Malawi [44] and for secondary distribution models, delivering
self-testing kits to sexual partners of antenatal clinic attendees
in South Africa [43]. The Blantyre study was in a setting of
high HIV prevalence and high levels of undiagnosed and
untreated PLHIV and assumed constant HIV incidence. That
analysis concluded that over a 20-year time horizon adding
CB-HIVST to facility-based testing was cost-effective and was
suited to early ART initiation strategies. In the South African
study, secondary distribution of self-testing kits to partners of
pregnant women became cost-saving when considering the
total cost of the HIV programme, although expenditure by the
testing programme was increased. These findings concur with
our current analysis, that community-based strategies target-
ing a large group of the population, such as young people and
adult men, achieve the greatest population level-impact in
terms of proportion diagnosed, but are not very cost-effective,
unless the prevalence of undiagnosed HIV is relatively high.
This work has limitations. As for any economic evaluation
which takes an appropriately long-time horizon, we rely on a
mathematical model to give predictions of the long-term
impact of the alternative implementation options. We consider
the implementation in three specific groups, which are either
underserved by current testing approaches or characterized
by a high incidence, but we could have considered slightly dif-
ferent groups.
5 | CONCLUSIONS
CB-HIVST provides a new option for reaching relatively
underserved sub-populations and can provide health benefits
cost-effectively if targeted to WTS,as well as adult men for a
limited time. The prevalence of undiagnosed HIV, assumptions
relating to linkage to prevention post-HIVST and the cost of
CB-HIVST are then critical in determining whether or not
wider intervention strategies, which have not only higher
potential benefits but also much higher costs, should be intro-
duced.
RECOMMENDATIONS
• Targeting adult men with community-based HIV self-testing
(CB-HIVST) tends to allow aversion of a large number of
infections as this is a large group which is currently under
tested.
• Linkage to voluntary medical male circumcision (VMMC) fol-
lowing a negative HIVST should be considered as this can
enhance the impact.
• Providing CB-HIVST to women having transactional sex
(WTS) offers the best value for money and should be imple-
mented.
• The introduction of CB-HIVST among adult men is cost-
effective, provided that the undiagnosed HIV prevalence is
above 3% or the distribution programme is limited to 5
years duration. Shortening the intervention period improves
the cost-effectiveness because as we continue testing at
the same rate the test positivity rate declines while the cost
(except for discounting) remains the same.
• At its current cost, introduction of CB-HIVST among young
people does not offer value for money.
• When deciding whether to implement CB-HIVST the overall
cost of CB-HIVST (not only the kit cost) should be consid-
ered as well as the current prevalence of undiagnosed HIV.
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